Literature DB >> 7939781

Immunetolerance as treatment of alloantibodies to factor VIII in hemophilia. The International Registry of Immunetolerance Protocols.

G Mariani1, E Scheibel, T Nogao, C K Kasper, N P Ewing, E Mauser-Bunschoten, A Ghirardini, R Bellocco, H H Brackman.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1994        PMID： 7939781

Source DB:  PubMed          Journal:  Semin Hematol        ISSN： 0037-1963            Impact factor:   3.851


× No keyword cloud information.
  7 in total

Review 1.  Immune tolerance therapy for haemophilia.

Authors:  A Y Ho; S E Height; M P Smith
Journal:  Drugs       Date:  2000-09       Impact factor: 9.546

2.  Gene-based FVIIa prophylaxis modulates the spontaneous bleeding phenotype of hemophilia A rats.

Authors:  Shannon M Zintner; Juliana C Small; Giulia Pavani; Lynn Dankner; Oscar A Marcos-Contreras; Phyllis A Gimotty; Mads Kjelgaard-Hansen; Bo Wiinberg; Paris Margaritis
Journal:  Blood Adv       Date:  2019-02-12

3.  Factor VIII inhibitors in hemophilia A: rationale and latest evidence.

Authors:  Char Witmer; Guy Young
Journal:  Ther Adv Hematol       Date:  2013-02

Review 4.  Management of haemophilia A-inhibitor patients: clinical and regulatory perspectives.

Authors:  Zera Tellier; Marie-Hélène André; Benoît Polack
Journal:  Clin Rev Allergy Immunol       Date:  2009-10       Impact factor: 8.667

Review 5.  Management of factor VIII inhibitors.

Authors:  Donna M Dimichele
Journal:  Int J Hematol       Date:  2006-02       Impact factor: 2.490

6.  Early eradication of factor VIII inhibitor in patients with congenital hemophilia A by immune tolerance induction with a high dose of immunoglobulin.

Authors:  Yoko Mizoguchi; Aya Furue; Reiko Kagawa; Ikue Chijimatsu; Keita Tomioka; Maiko Shimomura; Yusuke Imanaka; Shiho Nishimura; Satoshi Saito; Mizuka Miki; Atsushi Ono; Nakao Konishi; Hiroshi Kawaguchi; Masao Kobayashi
Journal:  Int J Hematol       Date:  2016-02-01       Impact factor: 2.490

7.  The changing face of immune tolerance induction in haemophilia A with the advent of emicizumab.

Authors:  Manuel Carcao; Carmen Escuriola-Ettingshausen; Elena Santagostino; Johannes Oldenburg; Ri Liesner; Beatrice Nolan; Angelika Bátorová; Saturnino Haya; Guy Young
Journal:  Haemophilia       Date:  2019-04-29       Impact factor: 4.287
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.